Essential package of diagnostic tests for bacterial and fungal infections and antimicrobial resistance

Overview

Access to reliable diagnostic testing for bacterial and fungal infections and antimicrobial susceptibility testing is essential to guide appropriate antimicrobial use, strengthen antimicrobial resistance surveillance and improve patient outcomes. Major gaps persist, especially in low- and middle-income countries. Building on the World Health Organization (WHO) model list of essential in vitro diagnostics, the WHO essential package of diagnostic tests for bacterial and fungal infections and antimicrobial resistance (EPD–AMR) is a prioritized catalogue of rapid, microscopy, culture-based, serological and molecular tests mapped to the tiers of the health system, from primary care to tertiary hospitals. By specifying test purpose, specimen type and methodology at each health system level, and outlining key considerations for national implementation, the EPD–AMR aims to guide policymakers, regulators, health-care providers and implementing partners in prioritizing and rolling out essential diagnostic services. Developed under the WHO Antimicrobial Resistance Diagnostic Initiative, the package supports equitable access to timely, quality-assured and accurate diagnosis, treatment and surveillance of bacterial and fungal infections and antimicrobial resistance